Bolt Biotherapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Bolt Biotherapeutics R&D Spending Growth & History (BOLT)
Bolt Biotherapeutics's r&d spending was $28.5M for fiscal 2025.
View full Bolt Biotherapeutics company overviewBolt Biotherapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $28.5M | −$28.9M | −50.35% |
| 2024 | 2024-12-31 | $57.5M | −$4.1M | −6.62% |
| 2023 | 2023-12-31 | $61.5M | −$11.6M | −15.84% |
| 2022 | 2022-12-31 | $73.1M | −$2.5M | −3.35% |
| 2021 | 2021-12-31 | $75.7M | $35.3M | +87.46% |
| 2020 | 2020-12-31 | $40.4M | — | — |
Bolt Biotherapeutics quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.1M | −$2.3M | −31.33% |
| Q1 2026 | 2026-03-31 | $4.8M | −$4.7M | −49.23% |
| Q4 2025 | 2025-12-31 | $5.0M | −$6.7M | −57.45% |
| Q3 2025 | 2025-09-30 | $6.5M | −$7.3M | −52.59% |
| Q2 2025 | 2025-06-30 | $7.5M | −$7.9M | −51.42% |
| Q1 2025 | 2025-03-31 | $9.5M | −$7.0M | −42.45% |
| Q4 2024 | 2024-12-31 | $11.7M | −$4.6M | −28.18% |
| Q3 2024 | 2024-09-30 | $13.8M | −$1.2M | −7.80% |
| Q2 2024 | 2024-06-30 | $15.4M | −$211,000 | −1.35% |
| Q1 2024 | 2024-03-31 | $16.5M | $1.9M | +13.02% |
| Q4 2023 | 2023-12-31 | $16.3M | −$523,000 | −3.10% |
| Q3 2023 | 2023-09-30 | $15.0M | −$4.0M | −21.20% |
| Q2 2023 | 2023-06-30 | $15.6M | −$3.3M | −17.32% |
| Q1 2023 | 2023-03-31 | $14.6M | −$3.8M | −20.45% |
| Q4 2022 | 2022-12-31 | $16.8M | −$5.6M | −25.08% |
| Q3 2022 | 2022-09-30 | $19.0M | −$364,000 | −1.88% |
| Q2 2022 | 2022-06-30 | $18.9M | −$787,000 | −3.99% |
| Q1 2022 | 2022-03-31 | $18.4M | $4.3M | +30.14% |
| Q4 2021 | 2021-12-31 | $22.5M | $7.6M | +51.26% |
| Q3 2021 | 2021-09-30 | $19.3M | $9.8M | +102.69% |
| Q2 2021 | 2021-06-30 | $19.7M | $10.5M | +115.00% |
| Q1 2021 | 2021-03-31 | $14.1M | $7.3M | +108.15% |
| Q4 2020 | 2020-12-31 | $14.9M | — | — |
| Q3 2020 | 2020-09-30 | $9.5M | — | — |
| Q2 2020 | 2020-06-30 | $9.2M | — | — |
| Q1 2020 | 2020-03-31 | $6.8M | — | — |
Bolt Biotherapeutics r&d spending trends
Over the last five fiscal years, Bolt Biotherapeutics's r&d spending decreased from $40.4M to $28.5M, a change of −$11.8M. The latest reported quarter, Q2 2026, shows $5.1M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bolt Biotherapeutics source filings ↗